Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors: a Retrospective Cohort Study.
Rui Zhao,Yong Wang,Yuqian Huang,Yaping Cui,Lin Xia,Yi Chen,Wen Zhuang,Yong Zhou,Xiaoting Wu
DOI: https://doi.org/10.1038/s41598-017-17266-5
IF: 4.6
2017-01-01
Scientific Reports
Abstract:The duration of adjuvant imatinib for high-risk patients with gastrointestinal stromal tumors (GISTs) is still controversial. Therefore, we retrospectively analyzed the data of high-risk patients with GISTs to investigate the appropriate duration. All 185 patients were divided into 4 groups: <1 year (Group A), 1-2 years (Group B), 2-3 years (Group C) and >3 years (Group D). The mean recurrence-free survival (RFS) in Groups A, B, and C were 44.3, 62.1, and 86.8 months, respectively (P < 0.001); the mean overall survival (OS) in Groups A, B and C was 75.2, 88.1, and 94.7 months, respectively (P = 0.009). The 5-year RFS in Groups A, B, C, and D was 15%, 26%, 83%, and 100%, respectively (P < 0.001); and the 5-year OS was 64%, 88%, 88%, and 100%, respectively (P < 0.001). The greatest impact on unfavorable outcomes was the tumor mitotic rate (HR, 2.01, 95% CI, 1.38-2.94; P < 0.001). Duration of adjuvant imatinib was the only favorable factor (HR, -0.95, 95% CI, 0.93-0.97; P < 0.001). For high-risk patients with high tumor size or mitotic rate, or non-gastric GISTs, we recommend that more than 3 years of adjuvant imatinib is feasible.